Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

The Effect of Periurethral Injection of Platelet Rich Plasma Versus Mid-urethral Sling in Treatment of Stress Urinary Incontinence

NCT07550426 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-04-15
Last updated
2026-07-22

Condition(s) studied

Stress Urinary Incontinence (SUI)

Investigational drug(s) / intervention(s)

Platelet Rich PlasmaMid urethral sling ( trans obturator tape)

Platelet Rich Plasma: GROUP 1 : 21patient will have platelet rich plasma injected periurethral in intrinsic muscle weakness in stress urinary incontinence

Mid urethral sling ( trans obturator tape): GROUP 2 : (21) patient having SUI due to hypermobile urethra will have TOT

Study summary

this study used to compare efficacy between platelet rich plasma periurethral injection versus mid urethral sling ( trans obturator tape ) in treatment of stress urinary incontinence

Eligibility

Sex
FEMALE
Min age
26 Years
Max age
66 Years
Healthy volunteers
No
Inclusion Criteria: * stress urinary incontinence identified by urodynamic study * patient agreement to undergo surgical treatment Exclusion Criteria: * previous GUS operation * evidence of detrusor overactivity urinary system * presence of pelvic organ prolapse * malignancies of genitourinary system * history of hemorrhagic disorders , on anti platelet treatment , uncontrolled diabetes mellitus .

Primary outcome measure(s)

  • objective assessment of urinary leakage through cough stress test — after one and three months

Trial sites (1)

FacilityCityRegionStatus
Ainshams university maternity hospital Cairo Abbassyia
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07550426 on ClinicalTrials.gov ↗ ← All trials in Egypt